VNDA PDUFA decision: a negative outcome, +2.7%

On February 1, 2026, Milsaperidone — Vanda Pharmaceuticals Inc. (Major Depressive Disorder (MDD)) reached its PDUFA decision. The result was a negative outcome, and the stock moved +2.7% in the window around the event. It had already run +10.7% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.